Evaluating the burden of illness of metabolic dysfunction–associated steatohepatitis in a large managed care population: The ETHEREAL Study
Compared with those of the non-MASH cohort with similar age, Quan Charlson Comorbidity Index, health plan, region of residence, and duration of enrollment, patients with MASH had significantly higher all-cause, CV-related, and liver-related hospitalizations and medical costs.
Authors
- Chioma Uzoigwe (ORCID: https://orcid.org/0000-0002-6853-7117)
- Anthony Hoovler (ORCID: https://orcid.org/0000-0002-8833-4923)
- Amy Articolo
- Rakesh Luthra
- Ivy Tonnu-Mihara (ORCID: https://orcid.org/0000-0002-8768-1990)
- Michael Charlton (ORCID: https://orcid.org/0000-0002-8766-7494)
- Feven Asefaha
- Ziqi Zhou (ORCID: https://orcid.org/0009-0008-2412-7002)
- Chia‐Chen Teng
Institutions
- University of Chicago (US)
- Novo Nordisk (United States) (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2024-09-27
- DOI
- https://doi.org/10.18553/jmcp.2024.24106
- Citations
- 2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- Bristol-Myers Squibb
- Pfizer
- Novo Nordisk